Drug Uncertainty Influences Patient Treatment Decisions

Adults are less likely to choose a cancer medication when provided with clear information about scientific unknowns.

Updated on Oct. 16, 2026 in Cancer

Gouache-painted illustration of a translucent glass heart silhouette, conveying the delicate nature of medical decision-making and scientific transparency. — A recent study in JAMA Internal Medicine reveals that disclosing scientific uncertainties about cancer medications significantly influences patient treatment decisions in the US. AI Illustration. Upload story photo >

Live Poll

Would you prefer to know all potential drug uncertainties before deciding to take a new medication?

A new study published in JAMA Internal Medicine finds that disclosing information about scientific uncertainties surrounding cancer drugs significantly impacts patient treatment decisions. The findings show that when US adults learn about potential unknowns regarding a medication, they are less likely to choose that treatment.

Why it matters

Understanding how uncertainty influences decisions helps patients and doctors have more transparent conversations about the benefits and risks of new therapies. By knowing exactly what data is missing, patients can better weigh their personal preferences against the limitations of current evidence.

This study of 6,272 U.S. adults utilized two clinical trials to measure how disclosure of scientific uncertainty affects treatment interest. Participants showed a mean 10.1 percentage point reduction in their willingness to take a medication when presented with specific information regarding drug uncertainties.

The players

JAMA Internal Medicine

A peer-reviewed medical journal that publishes research on healthcare policy and clinical outcomes.

The details

Participants in the study rated their likelihood of taking a drug before and after reviewing details on five specific categories of uncertainty. Researchers found that as patients learned about factors like limited study populations or unknown long-term improvement rates, their perceived trust and belief in the effectiveness of the drug decreased. Specifically, information about unknown patient improvement led to a 14.1 percentage point drop in interest, while lack of race or ethnicity data caused a 12.8 point decline.

May 9 to July 26, 2025: Study participants were recruited for the trials.
October 12, 2026: The research study was published in JAMA Internal Medicine.

Health Landscape

This research sits within the broader movement toward increased transparency in clinical drug labels and regulatory communications. Integrating these findings into the FDA website's existing drug information infrastructure could mark a shift in how medical evidence is presented to the public.

If you are considering a new cancer treatment, ask your physician specifically about any known uncertainties in the drug's clinical trial data, such as a lack of diversity in the study population or unknown long-term effects. Being aware of these limitations is a valid part of your medical decision-making process.

The takeaway

Transparency about scientific unknowns can change how you perceive a drug's value and your willingness to start a new therapy. When discussing new treatment options with your doctor, do not hesitate to ask what specific information is still missing from the clinical evidence.